‹ ›
MYP_105010
← PREVIOUS NEXT → BACK
Basic Information
P4-7
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiretroviral
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Standard
20 amino acids
C106H152N28O28S2
Standard
Sequence
WDRGNVTLLCDCPNGPWVWV
Physicochemical Analysis
2330.64 Da
4.21
-1.26
-1.49
-0.0629
-0.04
0.30
0.18
-5.19
82.50
0.1500
16500.00
16625.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
888.92
-5.68
32.0
29.0
65.0
164.0
8.0
21.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0246143 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Defensin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Bio-Activity Profile
Antiviral Antiretroviral
Inhibitory effect on HIV-1 replication in CEMx174-M7-R5 cells
PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0269680 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells
2.59 μM
IC50
PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0271203 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 (RU570) | TZM-bl cells
2.66 μM
IC50
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperPeptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. | Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. | J Virol. 2011 Jul;85(14):7037-47. | DOI:10.1128/JVI.02366-10 | PMID:21543477 PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0314328 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1(NL4-3):inhibition of HIV replication
3 μM
IC50
PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0330772 VERIFIED: YES
Provenance & Taxonomy
GB virus C [Virus]
54290
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Entry inhibitor
TZM-bl
Qualitative inhibition
PaperPeptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
FIRST PREV 1 2 3 NEXT LAST
Showing 5 records on this page · Page 2 of 3